Yasuaki Sagara1, Rachel A Freedman2, Ines Vaz-Luis2, Melissa Anne Mallory2, Stephanie M Wong2, Fatih Aydogan2, Stephen DeSantis2, William T Barry2, Mehra Golshan2. 1. Yasuaki Sagara, Melissa Anne Mallory, Fatih Aydogan, and Mehra Golshan, Brigham and Women's Hospital; Yasuaki Sagara, Harvard T.H. Chan School of Public Health; Rachel A. Freedman, Ines Vaz-Luis, Stephen DeSantis, and William T. Barry, Dana-Farber Cancer Institute, Boston, MA; Stephanie M. Wong, McGill University Health Centre, Montreal, Quebec, Canada; and Fatih Aydogan, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey. yasuaki@sagara.or.jp. 2. Yasuaki Sagara, Melissa Anne Mallory, Fatih Aydogan, and Mehra Golshan, Brigham and Women's Hospital; Yasuaki Sagara, Harvard T.H. Chan School of Public Health; Rachel A. Freedman, Ines Vaz-Luis, Stephen DeSantis, and William T. Barry, Dana-Farber Cancer Institute, Boston, MA; Stephanie M. Wong, McGill University Health Centre, Montreal, Quebec, Canada; and Fatih Aydogan, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.
Abstract
PURPOSE: Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to determine the survival benefit of RT after BCS on the basis of risk factors for local recurrence. PATIENTS AND METHODS: A retrospective longitudinal cohort study was performed to identify patients with DCIS diagnosed between 1988 and 2007 and treated with BCS by using SEER data. Patients were divided into the following two groups: BCS+RT (RT group) and BCS alone (non-RT group). We used a patient prognostic scoring model to stratify patients on the basis of risk of local recurrence. We performed a Cox proportional hazards model with propensity score weighting to evaluate breast cancer mortality between the two groups. RESULTS: We identified 32,144 eligible patients with DCIS, 20,329 (63%) in the RT group and 11,815 (37%) in the non-RT group. Overall, 304 breast cancer-specific deaths occurred over a median follow-up of 96 months, with a cumulative incidence of breast cancer mortality at 10 years in the weighted cohorts of 1.8% (RT group) and 2.1% (non-RT group; hazard ratio, 0.73; 95% CI, 0.62 to 0.88). Significant improvements in survival in the RT group compared with the non-RT group were only observed in patients with higher nuclear grade, younger age, and larger tumor size. The magnitude of the survival difference with RT was significantly correlated with prognostic score (P < .001). CONCLUSION: In this population-based study, the patient prognostic score for DCIS is associated with the magnitude of improvement in survival offered by RT after BCS, suggesting that decisions for RT could be tailored on the basis of patient factors, tumor biology, and the prognostic score.
PURPOSE: Radiotherapy (RT) after breast-conserving surgery (BCS) is a standard treatment option for the management of ductal carcinoma in situ (DCIS). We sought to determine the survival benefit of RT after BCS on the basis of risk factors for local recurrence. PATIENTS AND METHODS: A retrospective longitudinal cohort study was performed to identify patients with DCIS diagnosed between 1988 and 2007 and treated with BCS by using SEER data. Patients were divided into the following two groups: BCS+RT (RT group) and BCS alone (non-RT group). We used a patient prognostic scoring model to stratify patients on the basis of risk of local recurrence. We performed a Cox proportional hazards model with propensity score weighting to evaluate breast cancer mortality between the two groups. RESULTS: We identified 32,144 eligible patients with DCIS, 20,329 (63%) in the RT group and 11,815 (37%) in the non-RT group. Overall, 304 breast cancer-specific deaths occurred over a median follow-up of 96 months, with a cumulative incidence of breast cancer mortality at 10 years in the weighted cohorts of 1.8% (RT group) and 2.1% (non-RT group; hazard ratio, 0.73; 95% CI, 0.62 to 0.88). Significant improvements in survival in the RT group compared with the non-RT group were only observed in patients with higher nuclear grade, younger age, and larger tumor size. The magnitude of the survival difference with RT was significantly correlated with prognostic score (P < .001). CONCLUSION: In this population-based study, the patient prognostic score for DCIS is associated with the magnitude of improvement in survival offered by RT after BCS, suggesting that decisions for RT could be tailored on the basis of patient factors, tumor biology, and the prognostic score.
Authors: Yasuaki Sagara; Melissa Anne Mallory; Stephanie Wong; Fatih Aydogan; Stephen DeSantis; William T Barry; Mehra Golshan Journal: JAMA Surg Date: 2015-08 Impact factor: 14.766
Authors: Charles Harding; Francesco Pompei; Dmitriy Burmistrov; H Gilbert Welch; Rediet Abebe; Richard Wilson Journal: JAMA Intern Med Date: 2015-09 Impact factor: 21.873
Authors: Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava Journal: Lancet Oncol Date: 2014-05 Impact factor: 41.316
Authors: Kevin S Hughes; Lauren A Schnaper; Jennifer R Bellon; Constance T Cirrincione; Donald A Berry; Beryl McCormick; Hyman B Muss; Barbara L Smith; Clifford A Hudis; Eric P Winer; William C Wood Journal: J Clin Oncol Date: 2013-05-20 Impact factor: 44.544
Authors: M J Silverstein; M D Lagios; P H Craig; J R Waisman; B S Lewinsky; W J Colburn; D N Poller Journal: Cancer Date: 1996-06-01 Impact factor: 6.860
Authors: S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto Journal: Lancet Date: 2011-10-19 Impact factor: 79.321
Authors: Eileen Rakovitch; Sharon Nofech-Mozes; Wedad Hanna; Frederick L Baehner; Refik Saskin; Steven M Butler; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Martin C Chang; Susan J Robertson; Elzbieta Slodkowska; Cindy Fong; Joseph M Anderson; Farid Jamshidian; Dave P Miller; Diana B Cherbavaz; Steven Shak; Lawrence Paszat Journal: Breast Cancer Res Treat Date: 2015-06-29 Impact factor: 4.872
Authors: M J Cambra; F Moreno; X Sanz; L Anglada; M Mollà; V Reyes; M Arenas; A Pedro; R Ballester; V García; J Casals; M Cusidó; C Jimenez; J M Escribà; M Macià; J M Solé; A Arcusa; M A Seguí; S Gonzalez; B Farrús; A Biete Journal: Clin Transl Oncol Date: 2019-07-01 Impact factor: 3.405
Authors: Renée S J M Schmitz; Erica A Wilthagen; Frederieke van Duijnhoven; Marja van Oirsouw; Ellen Verschuur; Thomas Lynch; Rinaa S Punglia; E Shelley Hwang; Jelle Wesseling; Marjanka K Schmidt; Eveline M A Bleiker; Ellen G Engelhardt Journal: Cancers (Basel) Date: 2022-07-02 Impact factor: 6.575
Authors: Meena S Moran; Yinjun Zhao; Shuangge Ma; Youlia Kirova; Alain Fourquet; Peter Chen; Karen Hoffman; Kelly Hunt; Julia Wong; Lia M Halasz; Gary Freedman; Robert Prosnitz; Michael Yassa; David H A Nguyen; Tarek Hijal; Bruce G Haffty; Elaine S Wai; Pauline T Truong Journal: JAMA Oncol Date: 2017-08-01 Impact factor: 33.006
Authors: Dean A Shumway; Chandler M McLeod; Monica Morrow; Yun Li; Allison W Kurian; Aaron Sabolch; Ann S Hamilton; Kevin C Ward; Steven J Katz; Sarah T Hawley; Reshma Jagsi Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 8.013